HighTower Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.52M | Buy |
8,035
+1,252
| +18% | +$219K | ﹤0.01% | 1890 |
|
|
2025
Q4 | $1.15M | Buy |
6,783
+621
| +10% | +$95.2K | ﹤0.01% | 2017 |
|
|
2025
Q3 | $812K | Sell |
6,162
-1,195
| -16% | -$143K | ﹤0.01% | 2253 |
|
|
2025
Q2 | $781K | Sell |
7,357
-1,307
| -15% | -$142K | ﹤0.01% | 2186 |
|
|
2025
Q1 | $1.08M | Sell |
8,664
-984
| -10% | -$128K | ﹤0.01% | 1917 |
|
|
2024
Q4 | $1.19M | Buy |
9,648
+2,054
| +27% | +$242K | ﹤0.01% | 1854 |
|
|
2024
Q3 | $851K | Buy |
7,594
+2,060
| +37% | +$226K | ﹤0.01% | 2028 |
|
|
2024
Q2 | $592K | Sell |
5,534
-270
| -5% | -$29.7K | ﹤0.01% | 2196 |
|
|
2024
Q1 | $702K | Buy |
5,804
+647
| +13% | +$79.3K | ﹤0.01% | 2036 |
|
|
2023
Q4 | $625K | Sell |
5,157
-175
| -3% | -$21.8K | ﹤0.01% | 2158 |
|
|
2023
Q3 | $696K | Buy |
5,332
+1,120
| +27% | +$149K | ﹤0.01% | 1998 |
|
|
2023
Q2 | $513K | Buy |
4,212
+261
| +7% | +$35.1K | ﹤0.01% | 2181 |
|
|
2023
Q1 | $576K | Sell |
3,951
-93
| -2% | -$13.8K | ﹤0.01% | 2018 |
|
|
2022
Q4 | $641K | Buy |
4,044
+2,163
| +115% | +$317K | ﹤0.01% | 1956 |
|
|
2022
Q3 | $252K | Buy |
1,881
+2
| +0.1% | +$304 | ﹤0.01% | 2456 |
|
|
2022
Q2 | $295K | Buy |
1,879
+113
| +6% | +$17.4K | ﹤0.01% | 2377 |
|
|
2022
Q1 | $276K | Sell |
1,766
-521
| -23% | -$75.6K | ﹤0.01% | 2589 |
|
|
2021
Q4 | $295K | Sell |
2,287
-286
| -11% | -$37.6K | ﹤0.01% | 2482 |
|
|
2021
Q3 | $339K | Sell |
2,573
-58
| -2% | -$8.76K | ﹤0.01% | 2334 |
|
|
2021
Q2 | $465K | Buy |
2,631
+491
| +23% | +$85K | ﹤0.01% | 2089 |
|
|
2021
Q1 | $351K | Sell |
2,140
-4,330
| -67% | -$713K | ﹤0.01% | 2189 |
|
|
2020
Q4 | $1.06M | Sell |
6,470
-7,420
| -53% | -$1.11M | ﹤0.01% | 1232 |
|
|
2020
Q3 | $1.98M | Sell |
13,890
-6,229
| -31% | -$772K | 0.01% | 874 |
|
|
2020
Q2 | $2.22M | Sell |
20,119
-6,289
| -24% | -$695K | 0.01% | 772 |
|
|
2020
Q1 | $2.63M | Sell |
26,408
-11,726
| -31% | -$1.52M | 0.02% | 650 |
|
|
2019
Q4 | $5.68M | Buy |
38,134
+6,453
| +20% | +$878K | 0.03% | 502 |
|
|
2019
Q3 | $4.06M | Buy |
31,681
+12,397
| +64% | +$1.66M | 0.02% | 637 |
|
|
2019
Q2 | $2.75M | Buy |
19,284
+3,144
| +19% | +$423K | 0.02% | 782 |
|
|
2019
Q1 | $2.29M | Buy |
16,140
+1,541
| +11% | +$201K | 0.02% | 799 |
|
|
2018
Q4 | $1.78M | Sell |
14,599
-1,923
| -12% | -$285K | 0.01% | 807 |
|
|
2018
Q3 | $2.75M | Buy |
16,522
+527
| +3% | +$90.6K | 0.02% | 727 |
|
|
2018
Q2 | $2.72M | Buy |
15,995
+4,228
| +36% | +$691K | 0.02% | 733 |
|
|
2018
Q1 | $1.81M | Buy |
11,767
+900
| +8% | +$132K | 0.02% | 835 |
|
|
2017
Q4 | $1.47M | Sell |
10,867
-1,218
| -10% | -$169K | 0.01% | 931 |
|
|
2017
Q3 | $1.76M | Buy |
12,085
+5,184
| +75% | +$784K | 0.02% | 865 |
|
|
2017
Q2 | $1.08M | Buy |
6,901
+4,530
| +191% | +$693K | 0.01% | 1021 |
|
|
2017
Q1 | $347K | Buy |
+2,371
| New | +$309K | ﹤0.01% | 1484 |
|
|
2016
Q2 | – | Sell |
-4,741
| Closed | -$621K | – | 1907 |
|
|
2016
Q1 | $621K | Buy |
4,741
+144
| +3% | +$17.9K | ﹤0.01% | 1268 |
|
|
2015
Q4 | $645K | Buy |
+4,597
| New | +$637K | 0.01% | 1188 |
|
|
2015
Q3 | – | Sell |
-1,180
| Closed | -$208K | – | 1906 |
|
|
2015
Q2 | $208K | Buy |
+1,180
| New | +$212K | ﹤0.01% | 1340 |
|
|
2014
Q4 | – | Sell |
-13,014
| Closed | -$2.09M | – | 1630 |
|
|
2014
Q3 | $2.09M | Sell |
13,014
-5,788
| -31% | -$890K | 0.04% | 546 |
|
|
2014
Q2 | $2.76M | Buy |
18,802
+515
| +3% | +$71.4K | 0.05% | 454 |
|
|
2014
Q1 | $2.53M | Sell |
18,287
-10,032
| -35% | -$1.51M | 0.05% | 439 |
|
|
2013
Q4 | $3.58M | Buy |
28,319
+1,320
| +5% | +$137K | 0.07% | 301 |
|
|
2013
Q3 | $2.49M | Buy |
26,999
+2,767
| +11% | +$223K | 0.06% | 365 |
|
|
2013
Q2 | $1.76M | Buy |
+24,232
| New | +$1.48M | 0.05% | 423 |
|
Other funds holding JAZZ
VPM
VCM
EC
HighTower Advisors's JAZZ Position: Q1 2026 in Review
HighTower Advisors increased its Jazz Pharmaceuticals (JAZZ) stake by 18% in Q1 2026, buying an estimated $219K and bringing the position to 8,035 shares worth $1.52M. The position accounts for ﹤0.01% of the portfolio, ranked #1890.
HighTower Advisors first reported a position in JAZZ in Q2 2013 and has held it in 46 quarters since. The position peaked at $5.68M in Q4 2019. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.
- HighTower Advisors held 8,035 shares of Jazz Pharmaceuticals worth $1.52M as of Q1 2026.
- HighTower Advisors bought 1,252 Jazz Pharmaceuticals shares in Q1 2026, an estimated $219K.
- Jazz Pharmaceuticals made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #1890 holding.
- HighTower Advisors first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 46 quarters since.
- HighTower Advisors's Jazz Pharmaceuticals position peaked at $5.68M in Q4 2019.
- 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.
Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.